Berberine is a plant compound sold as a dietary supplement for blood sugar and blood fats. Reductions are consistent but shrink as starting values approach the optimal range — exactly where health-focused adults begin. Digestive upset is common and reversible; the serious hazards are raised levels of prescription medicines and rare heart-rhythm disturbances. Most trials were small, single-country and rated low quality; capsules often hold less than labelled. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 75–85 mg/dL (4.2–4.7 mmol/L) | Primary target; predicts response size |
| HbA1c | 4.8–5.3% | Three-month glucose average; confirms sustained change |
| Fasting insulin | 2–5 µIU/mL | Detects insulin resistance before glucose rises |
| LDL cholesterol | 70–100 mg/dL (1.8–2.6 mmol/L) | Main lipid target; largest measured berberine effect |
| Triglycerides | Below 80 mg/dL (0.9 mmol/L) | Most responsive lipid fraction |
| Apolipoprotein B | Below 80 mg/dL | Counts atherogenic particles; outperforms LDL when triglycerides are high |
| ALT and AST | ALT 10–26 U/L, AST 10–26 U/L | Liver enzymes; track fatty liver benefit and rule out injury |
| Total bilirubin | 0.3–1.0 mg/dL | Berberine displaces bilirubin from carrier protein |
| Potassium and magnesium | Potassium 4.0–4.5 mmol/L, magnesium 2.0–2.5 mg/dL | Low levels amplify the heart-rhythm risk |
| Corrected QT interval | Below 440 ms in men, below 460 ms in women | Detects the electrical recovery delay behind reported arrhythmias |
| eGFR | Above 90 mL/min/1.73 m² | Kidney filtration; governs clearance of interacting drugs |
| Drug level for narrow-margin medicines | No universal target — track against the individual's own pre-berberine trough | Berberine's enzyme inhibition raises these levels |
Cadence: Baseline panel before starting; glucose repeated at 4 weeks; full lipid panel and liver enzymes at 12 weeks; then every 3 to 6 months while use continues. Narrow-margin drug levels at 1 week and again at 4 weeks after starting or stopping.